Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Neorecormon Market Size Forecast: How Large Could The Market Become By 2030?
Rising rates of chronic kidney disease, an increase in anemia cases linked to chemotherapy, the expansion of dialysis treatment facilities, clinical confirmation of recombinant erythropoietin’s effectiveness, and growth in production capabilities for injectable biologics all fueled the period of expansion observed historically.
Rising numbers of elderly individuals susceptible to anemia, heightened need for sustained anemia treatments, improved availability of biologic medications, increased emphasis on patient well-being, and broader implementation of biosimilar-aligned therapeutic approaches are driving growth in the forecast period. Key developments include greater utilization of erythropoiesis-stimulating agents, expanding requirements for managing anemia in chronic kidney disease patients, growing acceptance of biologic injectables, extended treatment options for anemia linked to oncology, and a sharper focus on optimizing hemoglobin levels.
Download A Free Sample Report For Comprehensive Market Insights:
Neorecormon Market Demand Drivers Creating New Revenue Opportunities
The increasing occurrence of chronic kidney disease (CKD) is anticipated to boost the neorecormon market in the coming period. Chronic kidney disease (CKD) is a progressive disorder where kidney function diminishes over time, frequently resulting in anemia because of decreased erythropoietin production. This rise in CKD cases is influenced by elements such as an aging population and lifestyle-related illnesses. Neorecormon plays a critical role for individuals with chronic kidney disease (CKD) in enhancing their quality of life by addressing anemia-related complications that often emerge as the condition advances. For example, in June 2023, a report from Kidney Research UK, a non-profit organization based in the UK, revealed that around 7.2 million people in the UK suffer from chronic kidney disease, accounting for more than 10% of the population. Out of these, 3.25 million are in advanced stages, while an additional 3.9 million are in early stages. Moreover, the number of those affected by chronic kidney disease is expected to climb to 7.61 million by 2033. Consequently, the rising prevalence of chronic kidney disease (CKD) is set to propel the neorecormon market.
Neorecormon Market Driver: Increasing Healthcare Expenditures DrivingMarket Growth Due To Enhanced Access To Chronic Kidney Diseases-Related Anemia Treatments
A rise in healthcare expenditures is predicted to fuel the growth of the neorecormon market moving forward. Healthcare expenditures denote the total sum allocated to healthcare-related services, products, and activities over a defined timeframe, measured at individual, community, national, or global levels. This increase is propelled by factors like the growing incidence of chronic illnesses, an aging demographic, progress in medical innovations, and heightened demand for sophisticated treatments and healthcare services. Such expenditure growth improves access to therapies like neorecormon through expanded insurance coverage, lowered patient expenses, and increased funding for anemia management programs. This encourages early detection, broader uptake, and market expansion, particularly in developing economies. By way of illustration, the Office for National Statistics, a UK-based statistical body, reported in May 2023 that healthcare spending in the UK hit roughly $367 billion (£292 billion) in 2023, marking a 5.6% increase. Additionally, long-term health and social care expenditure saw a real-term rise of 2.8% in 2022. Hence, growing healthcare expenditure is expected to drive the neorecormon market.
Neorecormon Market Driver: Growing Aging Population Fueling Market Growth Due To Rising Susceptibility Of Kidney Disorders Among Elderly
An expanding aging population is anticipated to drive neorecormon market growth in the future. Aging refers to a natural process characterized by a gradual decline in physiological functions, heightening the vulnerability of older individuals to chronic conditions such as cancer and kidney diseases, which frequently precipitate anemia. The elderly demographic is increasing due to improvements in healthcare, longer life expectancies, and lower birth rates. Neorecormon, an erythropoiesis-stimulating agent (ESA), is essential for managing anemia by enhancing red blood cell generation, boosting energy levels, and improving treatment results for aged patients. As an example, in February 2025, the World Health Organization, an international public health entity headquartered in Switzerland, stated that global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and older worldwide is forecast to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the growing aging population will fuel the neorecormon market.
Neorecormon Market Segmentation: How Is The Market Structured Across Key Categories?
The neorecormon market covered in this report is segmented –
1) By Formulation: Injectable Solution, Pre-Filled Syringes
2) By Indication: Anemia Due To Chronic Kidney Disease (CKD), Anemia In Cancer Patients, Anemia Associated With Other Conditions
3) By End User Patients: Adult Patients, Pediatric Patients
4) By Distribution Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies
Neorecormon Market Competitive Landscape And Leading Companies
Major companies operating in the neorecormon market are F. Hoffmann-La Roche Ltd.
Access The Complete Neorecormon Market Report:
Neorecormon Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the neorecormon market in 2025. The regions covered in the neorecormon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model